Linked Life Data

1813439

Source:http://linkedlifedata.com/resource/pubmed/id/1813439

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1992-6-16
pubmed:abstractText
The aim of the study was to evaluate the efficacy of 5-aminosalicylic acid (5-ASA) in maintaining the remission in patients with inactive Crohn's disease over a period of three years, using either the Crohn's Disease Activity Index (CDAI) and or the Laboratory Index (LI). Thirty-eight patients entered in the study; 20 received 5-ASA 1.6 g/day and 18 no specific therapy. The patients were followed for three years. Of the patients, 86% presented a relapse, 80% in the 5-ASA group and 94% in the control group. Two patients requested surgical therapy. All patients with clinical relapse had CDAI greater than 150 and LI greater than 100. 5-Aminosalicylic acid was well tolerated and was able to protect from relapse up to 60% of the patients in the first year of therapy. When treatment with 5-ASA is prolonged for periods longer than one year a progressive increase in the number of patients who present relapse can be observed, but of the 5-ASA group, 80% of relapses occurred in the three years whereas the control group showed 94% relapses at the end of the first year.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0251-1649
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
200-2
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study.
pubmed:affiliation
Division of Gastroenterology, Unita Sanitaria Locale, Pisa, Italy.
pubmed:publicationType
Journal Article